For the first time ever

PhysioHeart goes USA!

We have some very exciting news to share: LifeTec Group™ just conducted their first-ever PhysioHeart™ experiment in the USA! As part of our plans to be more accessible in the US market, we have been supporting US-based medtech developers with our Cardiac BioSimulator sessions for a while now, but today we have successfully added the PhysioHeart™ to our US capabilities. A major benefit of the PhysioHeart™ over the Cardiac BioSimulator is that the heart is alive, with full contractility, intact electrophysiology and coronary perfusion. The Cardiac BioSimulator on the other hand is more practical in its use, and therefore more suitable for clinical training programs and very early device studies.

PhysioHeart and Clinical Imaging

As shown in the movie clip, the PhysioHeart platform is compatible to clinical imaging such as ultrasound and fluoroscopy, and this makes it a perfect model to study feasibility, usability and deliverability of new cardiovascular devicesin a clinically relevant setting. This can be highly interesting in the R&D phase as a partial substitute for early animal experiments, but can also add great value to clinical training.  Both the Cardiac BioSimulator and the PhysioHeart can be applied in such an image suite.

How can we help?

What's in it for you?

What's in it for you? If you are a cardiac device developer and are preparing for animal trials, then theCardiac BioSimulator and PhysioHeart™ can help you prepare and troubleshoot. These cardiac simulation models provide more anatomical freedom in humanizing the approach to the heart, and allows more and additional measurements and imaging than would be available in-vivo. Following a Cardiac BioSimulator study campaign, the PhysioHeart adds another level of realism; the interaction between device and living tissue, contractility, electrophysiology, and coronary perfusion can be investigatedex-vivo. Moreover, as there is no need to use live animals to learn that the device and delivery procedure can be applied successfully in a clinically relevant scenario, timelines can be shortened. In the subsequent animal trials, the focus can be fully on the animal's long-time response to an intervention you already know to be delivered succesfully. This ensures a smoother and quicker animal trial phase.

CEO

Jurgen de Hart

Head of MedTech Innovation

Marco Stijnen

Senior Research Engineer

Sjoerd van Tuijl

R&D Engineer

Bart Smeets

Please get in touch with Sheila for more information

Partner Relations Manager
Sheila Owen
Call at +31 6 48118219 or e-mail us

Leave a message!

©2021 LifeTec Group.  Legal  Credits